Understanding how certain immune cells contribute to lung problems caused by schistosomiasis.
The contribution of hypoxia inducible factor-1-dependent glycolysis in lung interstitial macrophages to the pathobiology of schistosomiasis-induced pulmonary hypertension.
This study is looking at how a specific protein in immune cells affects their energy use and may contribute to lung problems caused by schistosomiasis, with the goal of finding new ways to help treat this condition.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11046623 on NIH RePORTER |
What this research studies
This research investigates the role of a specific transcription factor, hypoxia inducible factor-1 (HIF-1), and its influence on glycolysis in lung interstitial macrophages, which are immune cells involved in schistosomiasis-induced pulmonary hypertension (Sch-PH). The study aims to uncover how HIF-1-dependent glycolysis may promote the development of Sch-PH by examining changes in these immune cells in both human and mouse models. By analyzing the behavior of these macrophages and their metabolic processes, the research seeks to identify potential therapeutic targets for treating this neglected tropical disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schistosomiasis or those experiencing pulmonary hypertension related to this condition.
Not a fit: Patients with pulmonary hypertension not related to schistosomiasis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for patients suffering from schistosomiasis-induced pulmonary hypertension.
How similar studies have performed: Previous research has shown promising results in understanding the role of metabolic pathways in other forms of pulmonary hypertension, suggesting potential for success in this novel approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Lee, Michael Hyunjean — University of California, San Francisco
- Study coordinator: Lee, Michael Hyunjean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.